Mucormycosis in organ and stem cell transplant recipients

Clinical Infectious Diseases

Volumn 54, Issue 11, 2012, Pages 1629-1636

  Lanternier, Fanny ^a,b,c   Sun, Hsin Yun ^e,f,g   Ribaud, Patricia ^a,h   Singh, Nina ^e   Kontoyiannis, Dimitrios P ⁱ   Lortholary, Olivier ^a,b,c,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b IHU Imagine   (France)

^c INSTITUT PASTEUR   (France)

^d CNRS   (France)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CYCLOSPORIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; POLYENE; POSACONAZOLE; RAPAMYCIN; STEROID; TACROLIMUS; VORICONAZOLE;

ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; FUNGUS CULTURE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE STATUS; INCIDENCE; INFECTION RISK; MUCOR; MUCORMYCOSIS; NONHUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHIZOPUS; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT INDICATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BODY FLUIDS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MUCORALES; MUCORMYCOSIS; ORGAN TRANSPLANTATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

EID: 84861041378     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis195     Document Type: Article

References (62)

1. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17:1859-69. Epub.
2. Lanternier F DE, Morizot G, Elie C, et al. Lortholary O and the French Mycosis study group. A global analysis of mucormycosis in France: the "RetroZygo study" (2005-2007). Clin Infect Dis 2012; S54:35-43.
3. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; S54:23-34.
4. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-53.
5. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503-9.
6. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis 2010; 50:1091-100.
7. Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15:1395-401.
8. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6: 2365-74.
9. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37:221-9.
10. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200:1002-11.
11. Jimenez C, Lumbreras C, Aguado JM, et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation 2002; 73:476-80.
12. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70:112-6.
13. Ko WJ, Chien NC, Chou NK, Wang SS, Chu SH, Chang SC. Infection in heart transplant recipients: seven years' experience at the National Taiwan University Hospital. Transplant Proc 2000; 32:2392-5.
14. Bertocchi M, Thevenet F, Bastien O, et al. Fungal infections in lung transplant recipients. Transplant Proc 1995; 27:1695.
15. Schowengerdt KO, Naftel DC, Seib PM, et al. Infection after pediatric heart transplantation: results of a multiinstitutional study. The Pediatric Heart Transplant Study Group. J Heart Lung Transplant 1997; 16: 1207-16.
16. Ruffini E, Baldi S, Rapellino M, et al. Fungal infections in lung transplantation. Incidence, risk factors and prognostic significance. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:181-90.
17. Nampoory MR, Khan ZU, Johny KV, et al. Invasive fungal infections in renal transplant recipients. J Infect 1996; 33:95-101.
18. Park BJ PP, Wannemuehler KA, Alexander BP, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17:1855-64.
19. Einollahi B, Lessan-Pezeshki M, Pourfarziani V, et al. Invasive fungal infections following renal transplantation: a review of 2410 recipients. Ann Transplant 2008; 13:55-8.
20. Ruping MJ, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65:296-302.
21. Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O. Healthcare-associated zygomycosis. Clin Infect Dis 2012; S54:44-54.
22. Shoham S, Hinestrosa F, Moore J Jr, O'Donnell S, Ruiz M, Light J. Invasive filamentous fungal infections associated with renal transplant tourism. Transpl Infect Dis 2010; 12:371-4.
23. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
24. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active anti-fungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60.
25. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39:425-9.
26. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-73.
27. Pagano L, Valentini CG, Posteraro B, et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009; 21:322-9.
28. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47:1041-50.
29. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161-70.
30. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24:307-12.
31. Uckay I, Chalandon Y, Sartoretti P, et al. Invasive zygomycosis in transplant recipients. Clin Transplant 2007; 21:577-82.
32. Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010; 16:1456-8.
33. Xhaard AL, Porcher R, Dannaoui E, et al. Mucormycosis after allo-geneic hematopoietic stem cell transplantation: a French Multicenter Cohort Study (2003-2008). Clin Microbiol Infect; revised.
34. Lanternier F, Lortholary O. Zygomycosis and diabetes mellitus. Clin Microbiol Infect 2009; 15(Suppl 5):21-5.
35. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Anti-microb Agents Chemother 2009; 53:3549-51.
36. Singh N, Sun HY. Iron overload and unique susceptibility of liver transplant recipients to disseminated disease due to opportunistic pathogens. Liver Transpl 2008; 14:1249-55.
37. Singh N, Wannstedt C, Keyes L, et al. Hepatic iron content and the risk of Staphylococcus aureus bacteremia in liver transplant recipients. Prog Transplant 2007; 17:332-6.
38. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111-8.
39. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Vor-iconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence 2011; 2:348-55.
40. Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199:1399-406.
41. Schlemmer F, Lagrange-Xelot M, Lacroix C, de La Tour R, Socie G, Molina JM. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 42:551-2.
42. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-11.
43. Sun HY, Aguado JM, Bonatti H, et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009; 9:2166-71.
44. Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010; 90:85-92.
45. Alexander BD, Schell WA, Siston AM, et al. Fatal Apophysomyces elegans infection transmitted by deceased donor renal allografts. Am J Transplant 2010; 10:2161-7.
46. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118:1216-24.
47. Garcia-Hermoso D, Dannaoui E, Lortholary O, Dromer F. Agents of systemic and subcutaneous mucormycosis and entomophthoromycosis. In: American Society for Microbiology, ed. Manual of clinical microbiology, 10th ed. Washington, DC: 2011, chapter 119.
48. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45:e101-4.
49. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47:3343-4.
50. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008; 52:1573-6.
51. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004; 89:207-14.
52. Skiada A, Lanternier F, Groll A, et al. Diagnosis and treatment of zy-gomycosis: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Submitted.
53. Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007; 51:1253-8.
54. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52: 3637-41.
55. Shoham S, Magill SS, Merz WG, et al. Primary treatment of zy-gomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2010; 48:511-7.
56. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-5.
57. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47:364-71.
58. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator defer-asirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117:2649-57.
59. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67:715-22.
60. Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE Jr, Spellberg B. Posaconazole mono-or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009; 53:772-5.
61. Chakrabarti A, Chatterjee SS, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J 2009; 85: 573-81.
62. Hammond S BL, Marty F. Mortality in hematologic malignancies and hematopoietic stem cell transplant patients with mucormycosis 2001-2009. Antimicrob Agents Chemother 2011; 55:5018-21.